MedTrace Logo

Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer

NCT00754702 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-09-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of metronomic oral vinorelbine taken three times a week plus daily lapatinib without break, as salvage treatment in patients with metastatic breast cancer.

Conditions

Interventions

DRUG

Vinorelbine

Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity

DRUG

Lapatinib

Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity

Sponsors & Collaborators

  • University Hospital of Crete

    lead OTHER

Principal Investigators

  • Dimitris Mavrudis, MD · University Hospital of Crete, Dep of Medical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00754702 on ClinicalTrials.gov